Slide 1: A Bioelectronic Medicine & Wellness Company
A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR Corporate Presentation May 2026
Slide 2: Forward Looking Statements
Forward Looking Statements In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions o
Slide 3: Investor Highlights
Investor Revenue Highlights A Bioelectronic $ Millions Medicine & Wellness Company $41.6 $32.0 $25.2 Focused on Multiple Indications Large and Growing Opportunity 1 $16.0 • FDA Cleared for the prevention and treatment of • $20 billion spent annually out-of-pocket for chronic $5.5 $8.6 primary headac
Slide 4: Bioelectronic Technologies
Bioelectronic Technologies Rx Products General Wellness General Wellness Nasdaq: ECOR 4 © 2019 electroCore. All rights reserved. 4 ECOR NASDAQ:
Slide 5: gammaCore Sapphire
gammaCore Sapphire 1st FDA-cleared non-invasive vagus nerve stimulator ▪ Fast acting, comfortable, easy to use hand-held option ▪ FDA Cleared for the prevention and treatment of primary headache in adults and adolescents ▪ No drug-drug interactions or drug-like side effects LEARN MORE ▪ Can be used
Slide 6: Quell Technology
Quell® Technology LEARN MORE First and only high-dose wearable neuromodulation device for chronic pain FDA Authorized, non-invasive solution for • ECOR expects to leverage its sales fibromyalgia, a large, underserved market channels, particularly the VA Hospital • Symptom relief beyond reduction in
Slide 7: Truvaga: Launched December 2022
Launched December 2022 with greater than $1M of sales in 2023 LEARN MORE Truvaga is a general wellness product and as such has not been evaluated by the US Food and Drug Administration. Truvaga products are not intended to diagnose, treat, cure, or prevent any disease or condition. Nasdaq: ECOR 7 ©
Slide 8: TAC-STIM: Accelerated Training, Sustained Attention, Reduced Fatigue
LEARN MORE TAC-STIM has been developed with support from the 711th Human Performance Wing Performance Optimization Branch of the United States Air Force to provide: • Accelerated Training • Sustained Attention • Reduced Fatigue • Improved Mood TAC-STIM is a general wellness product and as such has n
Slide 9: Active Channels With Revenue Growth Opportunities
Active Channels With Revenue Growth Opportunities Driving Rx sales in the Department of Defense and Community Care Network through the $2.9B VA roughly 1,300 Department of Veterans Affairs and Military Treatment Facilities; Significant opportunity to add fibromyalgia offering to VA channel (40% prev
Slide 10: Bioelectronic Technology – Pipeline of Possible FDA Clearances
Bioelectronic Technology – Pipeline of Possible FDA Clearances gammaCore is the Primary headache1 only FDA-cleared non-invasive Post-traumatic stress disorder (PTSD)2,3 VNS therapy in mild Traumatic Brain Injury (mTBI) 2 primary headache Symptoms of fibromyalgia1 Quell is the first and Chemotherapy
Slide 11: Broad Intellectual Property Portfolio
Broad Intellectual Property Portfolio electroCore owns all intellectual property on which the technology relies Expansive pioneering IP coverage of peripheral nerve stimulation and non-invasive, transdermal neuro- stimulation in the neck We have patent coverage extending beyond 2040: >300 • Non-inva
Slide 12: Strategic Catalysts
Strategic Catalysts • R&D • Indications such as PTSD, mTBI, and Long COVID • Product such as Quell OTC and potential business development opportunities similar to the Quell transaction • Features including the new mobile platform for Truvaga • Commercial • Acceleration of revenue from the VA • Depar
Slide 13: Revenue Growth
Revenue Growth Net Sales $ in thousands 30% $41,600 5-year TTM CAGR: 57% >50% $32,032 87% 58% $25,182 56% $16,030 46% $8,592 $5,451 $3,496 $2,390 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025E FY 2026E* Nasdaq: *Guidance as of May 6, 2026 ECOR13 © 2019 electroCore. All rights reserved. 1 E
Slide 14: Capitalization Table
Capitalization Table Fully diluted as of May 1, 2026 (in thousands) Common Shares* 8,296 Pre-Funded Warrants 883 Warrants 1,454 Average Exercise price = $5.19 Options 516 Average Exercise price = $32.65 Restricted and Deferred RSUs/DSUs which vest through 682 Stock Units January 2029 Total 11,831 *E
Slide 15: Experienced Management Team
Experienced Management Team Thomas J. Errico, MD Joshua Lev Michael Fox Peter Staats Chairman, Founder and Interim President & Chief Operating Chief Medical Officer Principal Investor Chief Financial Officer Officer Nasdaq: ECOR15 © 2019 electroCore. All rights reserved. 1 ECOR NASDAQ:
Slide 16: A Bioelectronic Medicine & Wellness Company – Appendix
A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR Appendix 16
Slide 17: TAM Sources
TAM Sources VHA Data: • Migraine Is a Commonly Treated Condition Among Veterans (Nov. 2022) https://www.usmedicine.com/current-issue/vha-data-migraine-is-a-commonly-treated-condition-among- veterans/ • https://www.polytrauma.va.gov/headache/ • https://pubmed.ncbi.nlm.nih.gov/34606694/ Stress: • US: